MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/122.5/0.1/20.12.24 | Real-time Bid/Ask 07:16:30 2024-06-07 EDT | ||
| 0.151 EUR / 0.167 EUR | +8.16% |
|
| Current month | +13.95% | ||
| 1 month | +59.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 0.145 | -1.36% |
| 24-06-06 | 0.147 | +2.08% |
| 24-06-05 | 0.144 | +9.92% |
| 24-06-04 | 0.131 | -2.96% |
| 24-06-03 | 0.135 | +4.65% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 05:15 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MG0KGG |
| ISIN | DE000MG0KGG0 |
| Date issued | 2024-03-21 |
| Strike | 122.5 $ |
| Maturity | 2024-12-20 (197 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.29 € |
|---|---|
| Lowest since issue | 0.075 € |
| Spread | 0.014 € |
| Spread % | 8.48% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.68
USD
Average target price
96.31
USD
Spread / Average Target
+9.84%
- Stock Market
- Warrants
- Warrant
